Presbyterian Kaseman Hospital - New Mexico Cancer Research Alliance (NMCRA)

Albuquerque, NM

Not yet accepting

OPTIMMAL

An Open-Label, Non-Randomized, Multicenter, Phase II Study to Study the Efficacy of Talquetamab (JNJ-64407564) and Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (OPTIMMAL)
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Maintenance
  • Phase 2